Safety and efficacy of teriparatide in dialysis patients with osteoporosis

Safety and efficacy of teriparatide in dialysis patients with osteoporosis - Teriparatide for dialysis patients with osteoporosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009907

Enrollment

Registered

2013-01-30

Start date

2013-01-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low-PTH osteoporosis in dialysis patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Intact PTH lower than 60 pg/ml 2. Osteoporosis (T score <-2.5) 3. Low bone mass (T-score between -1.0 and -2.5 at the femoral neck or spine) with fragility fracture, with family history of proximal femur fracture, or with more than 15% of FRAX score (10-year probability of a major osteoporosis-related fracture).

Exclusion criteria

Exclusion criteria: 1. Dialysis vintage less than 1 year 2. Patietns with Paget's disease or having high alkaline phosphatase. 3. Previous history of radiation therapy affecting bone. 4. Bone related malignancy, including bone metastasis

Design outcomes

Primary

Measure	Time frame
Change of bone mineral density	—

Secondary

Measure	Time frame
Change of serum marker related to bone metabolism. Incidence of bone fracture after teriparatide therapy. Incidence of lumbago and abdominal pain. Side-effect and tolerance rate	—

Countries

Japan

Contacts

Public ContactJunichi Hoshino

Toranomon Hospital Nephrology Center

hoshino@toranomon.gr.jp+81-3-3588-1111

Outcome results